210 related articles for article (PubMed ID: 24029727)
1. Tau immunotherapy and imaging.
Sigurdsson EM
Neurodegener Dis; 2014; 13(2-3):103-6. PubMed ID: 24029727
[TBL] [Abstract][Full Text] [Related]
2. Tau Immunotherapy.
Sigurdsson EM
Neurodegener Dis; 2016; 16(1-2):34-8. PubMed ID: 26551002
[TBL] [Abstract][Full Text] [Related]
3. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.
Sigurdsson EM
Curr Alzheimer Res; 2009 Oct; 6(5):446-50. PubMed ID: 19874269
[TBL] [Abstract][Full Text] [Related]
4. Tau immunotherapy for Alzheimer's disease.
Pedersen JT; Sigurdsson EM
Trends Mol Med; 2015 Jun; 21(6):394-402. PubMed ID: 25846560
[TBL] [Abstract][Full Text] [Related]
5. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
6. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.
Dai CL; Hu W; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2018 Jan; 10(1):13. PubMed ID: 29386065
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.
Sigurdsson EM
J Alzheimers Dis; 2008 Oct; 15(2):157-68. PubMed ID: 18953105
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model.
Boutajangout A; Quartermain D; Sigurdsson EM
J Neurosci; 2010 Dec; 30(49):16559-66. PubMed ID: 21147995
[TBL] [Abstract][Full Text] [Related]
10. Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.
Schroeder SK; Joly-Amado A; Gordon MN; Morgan D
J Neuroimmune Pharmacol; 2016 Mar; 11(1):9-25. PubMed ID: 26538351
[TBL] [Abstract][Full Text] [Related]
11. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models.
Sankaranarayanan S; Barten DM; Vana L; Devidze N; Yang L; Cadelina G; Hoque N; DeCarr L; Keenan S; Lin A; Cao Y; Snyder B; Zhang B; Nitla M; Hirschfeld G; Barrezueta N; Polson C; Wes P; Rangan VS; Cacace A; Albright CF; Meredith J; Trojanowski JQ; Lee VM; Brunden KR; Ahlijanian M
PLoS One; 2015; 10(5):e0125614. PubMed ID: 25933020
[TBL] [Abstract][Full Text] [Related]
12. Harnessing the immune system for treatment and detection of tau pathology.
Congdon EE; Krishnaswamy S; Sigurdsson EM
J Alzheimers Dis; 2014; 40 Suppl 1(0):S113-21. PubMed ID: 24603943
[TBL] [Abstract][Full Text] [Related]
13. Tau immunotherapies: Lessons learned, current status and future considerations.
Sandusky-Beltran LA; Sigurdsson EM
Neuropharmacology; 2020 Sep; 175():108104. PubMed ID: 32360477
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for Alzheimer's disease.
Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
[TBL] [Abstract][Full Text] [Related]
15. Antibody Therapeutics Targeting Aβ and Tau.
Gallardo G; Holtzman DM
Cold Spring Harb Perspect Med; 2017 Oct; 7(10):. PubMed ID: 28062555
[TBL] [Abstract][Full Text] [Related]
16. [Development of antibodies for immunotherapy of Alzheimer's disease].
Matsumoto SE; Jin H; Takeda K; Hasegawa Y; Motoi Y; Hattori N; Tabira T
Rinsho Shinkeigaku; 2012; 52(11):1168-70. PubMed ID: 23196552
[TBL] [Abstract][Full Text] [Related]
17. Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly.
Congdon EE; Jiang Y; Sigurdsson EM
Semin Cell Dev Biol; 2022 Jun; 126():125-137. PubMed ID: 34896021
[TBL] [Abstract][Full Text] [Related]
18. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.
Boutajangout A; Ingadottir J; Davies P; Sigurdsson EM
J Neurochem; 2011 Aug; 118(4):658-67. PubMed ID: 21644996
[TBL] [Abstract][Full Text] [Related]
19. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
[TBL] [Abstract][Full Text] [Related]
20. Tau Proteins and Tauopathies in Alzheimer's Disease.
Chong FP; Ng KY; Koh RY; Chye SM
Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]